Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review

Takahisa Niimoto; Takafumi Todaka; Hirofumi Kimura; Shotaro Suzuki; Shumpei Yoshino; Kosuke Hoashi; Hirotaka Yamaguchi

doi:10.1186/s12245-024-00691-5

Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review

Int J Emerg Med. 2024 Sep 2;17(1):106. doi: 10.1186/s12245-024-00691-5.

Authors

Takahisa Niimoto^{1

2}, Takafumi Todaka³, Hirofumi Kimura³, Shotaro Suzuki⁴, Shumpei Yoshino⁴, Kosuke Hoashi⁵, Hirotaka Yamaguchi³

Affiliations

¹ Department of General Internal Medicine, Aso Iizuka Hospital, 3-83, Yoshio-Machi, Iizuka, Fukuoka, 820-8505, Japan. niimoto@outlook.jp.
² Department of Intensive Care Medicine, Aso Iizuka Hospital, 3-83, Yoshio-Machi, Iizuka, Fukuoka, 820-8505, Japan. niimoto@outlook.jp.
³ Department of General Internal Medicine, Aso Iizuka Hospital, 3-83, Yoshio-Machi, Iizuka, Fukuoka, 820-8505, Japan.
⁴ Department of Intensive Care Medicine, Aso Iizuka Hospital, 3-83, Yoshio-Machi, Iizuka, Fukuoka, 820-8505, Japan.
⁵ Department of Hematology, Aso Iizuka Hospital, 3-83, Yoshio-Machi, Iizuka, Fukuoka, 820-8505, Japan.

Abstract

Background: Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ failure, which is triggered by immunotherapy or certain infections. Immune checkpoint inhibitors rarely cause immune-related adverse event- cytokine release syndrome (irAE-CRS). This article presents a case report of irAE-CRS triggered by coronavirus disease 2019 (COVID-19).

Case presentation: A 60-year-old man with type 2 diabetes received nivolumab treatment for esophagogastric junction carcinoma and experienced two immune-related adverse events: hypothyroidism and skin disorder. Eleven days before his visit to our hospital, he had a fever and was diagnosed with COVID-19. Five days before his visit, he developed a fever again, along with general malaise, water soluble diarrhea, and myalgia of the extremities. On admission, the patient was in a state of multiple organ failure, and although the source of infection was unknown, a tentative diagnosis of septic shock was made. The patient's condition was unstable despite systemic management with antimicrobial agents, high-dose vasopressors, and intravenous fluids. We suspected CRS due to irAE (irAE-CRS) based on his history of nivolumab use. Steroid pulse therapy (methylprednisolone 1 g/day) was started, and the patient temporarily recovered. However, his respiratory condition worsened; consequently, he was placed on a ventilator and tocilizumab was added to the treatment. His muscle strength recovered to the point where he could live at home, and was subsequently discharged.

Conclusion: In patients previously treated with immune checkpoint inhibitors, irAE-CRS should be considered as a differential diagnosis when multiple organ damage is observed in addition to inflammatory findings. It is recommended to start treatment with steroids; if the disease is refractory, other immunosuppressive therapies such as tocilizumab should be introduced as early as possible.

Keywords: Cytokine release syndrome; Immune checkpoint inhibitor; Immune-related adverse event.